Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis (Q28267699)

2

0 references

G van der Horst

3

0 references

H Cheung

4

0 references

C van den Hoogen

5

0 references

G van der Pluijm

6

0 references

P Ten Dijke

Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response

7

0 references

language of work or name

English

0 references

publication date

4 March 2010

0 references

published in

Oncogene

0 references

volume

29

0 references

issue

9

0 references

page(s)

1351-61

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038/ONC.2009.426

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/ONC.2009.426

Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/ONC.2009.426

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/ONC.2009.426

Smad transcription factors

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/ONC.2009.426

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/ONC.2009.426

New insights into TGF-beta-Smad signalling

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/ONC.2009.426

Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/ONC.2009.426

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

TGF-beta and BMP7 interactions in tumour progression and bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Osteotropic cancers: from primary tumor to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Smad3 is a key nonredundant mediator of transforming growth factor beta signaling in Nme mouse mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

A multigenic program mediating breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Molecular biology of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Smad3 mediates TGF-beta1 induction of VEGF production in lung fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Transforming growth factor-beta signaling in cancer invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Invasion and metastasis of a mammary tumor involves TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Metastasis is driven by sequential elevation of H-ras and Smad2 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

The roles of Smad2 and Smad3 in the development of chemically induced skin tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

TGF beta-1 regulation of VEGF production by breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor- Type I Receptor Kinase In vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Microarray analysis of gene expression during epithelial-mesenchymal transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426

Serum levels of transforming growth factor beta1 in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.426